| Ytd | -11.98% | |
| 1y | -44.40% |
| Open | 0.69 | Prev Close | 0.68 | Low | 0.67 | High | 0.70 | Mkt Cap | 7.64M |
| Vol | 99.13K | Avg Vol | 572.43K | EPS | -2.57 | P/E | -0.27 | Forward P/E | 15.32 |
| Beta | 1.66 | Short Ratio | 1.23 | Inst. Own | 13.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.57 | 200-d Avg | 0.84 | 1yr Est | 54.00 |
CTXR News
New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-univer
Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market sessio
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. b
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. b
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncolo
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and f
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citiu
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distr
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius P
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after the company announced a register
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius P
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribin
Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get
Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinica
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LY
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonst
Non-dilutive capital supports continued execution and value creation CRANFORD, N.J., Feb. 24, 2026 /
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides f
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides f
Third international distribution agreement further advances global access strategy with major market
PainReform (NASDAQ: PRFX - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Repo
On Tuesday, 386 stocks made new 52-week lows.
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in
Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018
35 Stocks Moving In Monday's Mid-Day Session